IP Library Granted Patent US 11,246,476
Granted Patent B2
US 11,246,476 · App. 16/259,483 · Granted Feb 15, 2022

Method for visualizing tissue with an ICG dye composition during ablation procedures

Inventor: Gerald Melsky (Lexington, MA)
Assignee: CARDIOFOCUS, INC.
A61B1/043A61B1/0638A61B5/0036A61B5/0071A61B5/0084A61B18/20A61B1/0005A61B90/30A61B90/361A61B2017/00061A61B2018/00577A61B2018/00982A61B2090/373A61B2090/376A61B2090/3941
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,246,476
App. No.
16/259,483
Granted
Feb 15, 2022
Kind
B2
Abstract

A system is provided for identifying the sufficiency of lesions formed during a tissue ablation procedure. The system and method include administering an ICG composition to the patient and forming one or more lesions at a surgical site. The method further includes applying energy of a type and in an amount sufficient to cause ICG in the patient to fluoresce. An image of the tissue and lesion at the surgical site is obtained while the ICG fluoresces. The lesion is distinguished from surrounding de novo tissue based on areas of fluorescence to allow a user to evaluate the quality of the lesion.

Claims (16)

1. A method for distinguishing lesions from de novo tissue comprising the steps of:

administering an ICG composition to the patient;

forming one or more lesions at a surgical site;

applying energy of a type and in an amount sufficient to cause ICG in the patient to fluoresce;

obtaining an image of the tissue and lesion at the surgical site while the ICG fluoresces; and

distinguishing the lesion from surrounding de novo tissue based on areas of fluorescence to allow a user to evaluate the quality of the lesion and to identify one or more breaks in the lesion that indicate an incomplete, non-continuous lesion is formed, each break in the lesion being identified as an area of fluorescence between parts of the lesion that define the break; and

completing the lesion by ablating the tissue within the one or more breaks in the lesion until there is a lack of fluorescence between parts of the lesion that define the respective break.

2. The method of claim 1 , wherein areas of the lesion are characterized by a lack of fluorescence.

3. The method of claim 1 , wherein blood and the de novo tissue are characterized by areas of fluorescence.

4. The method of claim 1 , wherein the step of applying energy comprises applying light that has a wavelength that is sufficient to cause the ICG to fluoresce.

5. The method of claim 1 , wherein the image is in real-time.

6. The method of claim 1 , further including the step of filtering light that is captured by an imaging device to limit the light to a wavelength at which ICG fluoresces.

7. The method of claim 1 , further including the step of processing the filtered light to produce the image.

8. The method of claim 6 , wherein the wavelength is about 805 nm.

9. The method of claim 1 , wherein a common ablation instrument includes both an energy emitter for forming the lesion and a light beam for applying energy of the type and in the amount sufficient to cause the ICG composition to fluoresce.

10. The method of claim 1 , wherein an image processor receives the images from endoscope of the surgical site and is configured to combine both visible light images of the surgical site which show anatomical landmarks with fluorescence images obtained with excitation light used to cause ICG in the patient to fluoresce and display the combined images as a single combined image, thereby allowing the one or more breaks in the lesion to be seen over the anatomical landmarks.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: MELSKY, GERALD
To: CARDIOFOCUS, INC.
Reel/Frame 056274/0843 →
Cited By (1)
US 12,295,553